Science3 publishersIndependently confirmed2 min readPublished Updated
Phase III for a bespoke mRNA cancer therapy repriced the sequencing vendors, not just Moderna
Merck and Moderna put out no efficacy figures. Illumina still rose 16% and PacBio 18%, because an approved per-patient therapy implies a sequencing run per patient.
The Scientist · Science desk
What happened
- Merck and Moderna reported what they called the first positive Phase III result for an individualized mRNA neoantigen therapy, intismeran autogene given with Keytruda.
- In INTerpath-001, the combination beat Keytruda alone on the primary endpoint of recurrence-free survival and on distant metastasis-free survival.
- Neither company released figures for either arm; the data goes to an unnamed international medical meeting and to regulators.
- Between the Wednesday announcement and Friday, Illumina rose 16% and Pacific Biosciences 18%.
- Oxford Nanopore rose 39% over the same stretch, from 122.20 pounds to 170 pounds.
Compiled by The ScientistSomething wrong?How this is made
Why it matters
- capability Sequencing suppliers gain an oncology demand line that scales with patients dosed rather than with trials running, which is why they traded on someone else's readout.
- cost Per-patient tumor sequencing stops being a sponsor's research expense and becomes a per-dose manufacturing input that has to be defended on price for as long as the therapy is sold.
- contradiction The largest vendor move is the least usable evidence: GEN credits Oxford Nanopore's jump partly to its own results and a licence deal, leaving Illumina and PacBio as the cleaner read on the therapy.
- exposure Because the vendor re-rating rests on a result nobody outside the sponsors has seen in numbers, the first disclosed effect sizes will reprice consumables suppliers as well as Merck and Moderna.
Moderna's December 2023 Phase IIb data in stage III/IV melanoma, reported with the same partner, moved its stock 10% [14]. The Phase III headline moved it 130.5% across three sessions [13], about thirteen times as much [17], and it did so on the strength of a phase label rather than a hazard ratio.
What the sequencing vendors are buying is not what Moderna shareholders are buying. Intismeran is assembled for each patient from the mutations in that patient's own tumor, which is the link GEN draws between the sponsors' news and the instrument makers [26]. Vendor revenue therefore tracks the number of patients treated rather than the size of the benefit each one receives: a modest effect across a broad label sells more sequencing than a large effect in a narrow one. That also moves the sequencing bill from a study budget into the recurring input cost of every dose manufactured.
Oxford Nanopore is the leg of the rally to discount. Its 39% gain came with a first-half revenue increase of 10.5%, to 116.7m pounds [7], CEO Francis Van Parys restating a target above 700m pounds by 2030 [8], and an intellectual property cross-licence with an undisclosed diagnostics developer [9]. The disclosed cash in that licence is $35m [22], roughly 22% of the half-year's revenue [23], though it lands between the second half of 2026 and 2028. The 2030 target implies about 24.6% compound annual growth from the current half-year run rate [24], against the 10.5% just delivered [7]. Personalised oncology is one of the few end markets big enough to close a gap of that shape, which is precisely why the share price is a poor instrument for measuring it.
The give-back is the part worth keeping. The $45bn added to Moderna's market value on announcement day implies a pre-announcement equity value near $25.4bn [10][18]; by Friday's close about $33bn of that increase remained, with roughly $12bn gone [19]. Peak to Friday is a 16.8% decline [20], after a 24% single-day drop that GEN attributes to profit-taking and to a broad market fall on expectations of a longer Iran war [12]. Of the two upgrades, William Blair's Myles Minter went to Outperform, calling the update a clear positive for Moderna's fundamental business [15], while BofA's Alec Stranahan went only as far as Neutral with a $170 twelve-month target [16], about 17% above where the shares finished the week [25]. The most quoted phrase of the week, "a watershed moment", arrived attached to that Neutral rating [16].
What to watch
- The disclosed effect size and, more important for sequencing volume, how broad an indication Merck and Moderna file for once the data is presented.
- Whether Illumina or Pacific Biosciences quantify neoantigen-therapy sequencing in guidance, rather than leaving it as an implied tailwind.
- Whether Oxford Nanopore's cross-licence counterparty is named and the $20m in fees lands in H2 2026 as stated.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence45
- Adoption
- Insufficient
- Hype gap+40
- Incentives55
- Confidence55
Perspective Coverage
3 publishers- Builder
- Builder 27%
- Operator
- Operator 32%
- Investor
- Investor 41%
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
Merck and Moderna announced what they said were the first-ever positive Phase III results for an mRNA-based individualized neoantigen therapy (INT), intismeran autogene, given with Keytruda (pembrolizumab).
- [2]
In the Phase III INTerpath-001 trial (NCT05933577), patients on intismeran plus Keytruda showed greater improvement than patients on Keytruda alone, surpassing Keytruda on the primary endpoint of recurrence-free survival and on the key secondary endpoint of distant metastasis-free survival.
- [3]
Merck and Moderna did not share any specific data for either the intismeran-plus-Keytruda arm or the Keytruda-alone arm; the companies said the data will be presented at an upcoming international medical meeting, which analysts speculated could be ESMO or SITC, and shared with regulators.
- [4]
Between Wednesday's announcement and Friday, Illumina shares jumped 16%, from $188.29 to $219.40.
- [5]
Over the same period, Pacific Biosciences shares climbed 18%, from $1.14 to $1.35.
- [6]
Oxford Nanopore Technologies rose 39%, from 122.20 pounds ($166.68) to 170 pounds ($231.97), for reasons GEN said go beyond Merck-Moderna, including a strong first-half earnings report and other positive announcements.
- [7]
Oxford Nanopore announced a 10.5% revenue increase for the first half of this year, from 105.6m pounds ($144m) to 116.7m pounds ($159.2m).
- [8]
New Oxford Nanopore CEO Francis Van Parys restated a commitment to grow annual revenue to more than 700m pounds ($955m+) by 2030.
- [9]
Oxford Nanopore signed an intellectual property cross-licensing agreement with an undisclosed diagnostics developer that agreed to pay $20m in fees to be included in H2 2026 results, plus $15m in committed purchases in 2027-2028, plus low- to mid-single-digit royalties.
- [10]
The announcement sent Moderna's shares up 177% to $174.38, adding $45bn to the company's market capitalization.
- [11]
In the year preceding the announcement, Moderna shares had risen 124%, from $28.09 to $62.96.
- [12]
Moderna shares fell nearly 24% the following day to $133.32 on a combination of profit-taking and expectations of a longer Iran war that sank most of the markets.
- [13]
Moderna's stock rose 9% on Friday to finish the week at $145.13, a 130.5% three-day gain.
- [14]
In December 2023, when Moderna joined Merck to report positive Phase IIb data in stage III/IV melanoma, Moderna's shares rose 10%.
- [15]
William Blair partner and biotechnology analyst Myles R. Minter called the update a clear positive for Moderna's shares and fundamental business, and upgraded the stock from Market Perform to Outperform.
- [16]
BofA Securities vp of equity research Alec Stranahan upgraded the firm's rating on Moderna from Underperform to Neutral with a 12-month price target of $170, calling the announcement a watershed moment for Moderna, as reported by Forbes.
- [17]
Moderna's 130.5% three-day gain on the Phase III readout is about 13 times the 10% gain it saw on the December 2023 Phase IIb readout.
- [18]
A 177% move that added $45bn implies a pre-announcement equity value of about $25.4bn, and a post-announcement value of about $70.4bn.
- [19]
At Friday's 130.5% three-day gain, about $33bn of the $45bn added market value remained, meaning roughly $12bn came back off.
- [20]
Moderna's Friday close of $145.13 is 16.8% below its announcement-day close of $174.38.
- [21]
Illumina's 16% three-day gain is about one-eighth of Moderna's 130.5% three-day gain.
- [22]
The disclosed cash in Oxford Nanopore's cross-licensing agreement totals $35m before royalties.
- [23]
That $35m is about 22% of Oxford Nanopore's reported first-half revenue of $159.2m, spread over H2 2026 to 2028.
- [24]
Reaching more than 700m pounds by 2030 from a first-half run rate of 116.7m pounds (about 233.4m pounds annualised) requires roughly a tripling, or about 24.6% compound annual growth over five years, versus the 10.5% first-half growth reported.
- [25]
BofA's $170 price target sits about 17% above Moderna's Friday close of $145.13.
- [26]
GEN reported that the Merck-Moderna surge extended to sequencing companies including Illumina and Pacific Biosciences because intismeran is a personalized cancer therapy made for each patient based on the individual genetic mutations of their tumors.
Sources
3 independent publishers whose own reporting we read for this story.
- genengnews.comStockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too
1 article · August 23, 2026
- sciencenews.orgA new cancer vaccine may keep melanoma from coming back
1 article · August 25, 2026
- statnews.comSTAT+: Inside Moderna and Merck’s cancer vaccine triumph
1 article · August 24, 2026
Topics and entities
Follow any of these and your For You feed starts watching them — no settings page required.